share_log

Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $45

Benzinga ·  Nov 3, 2023 06:42

Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and lowers the price target from $52 to $45.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment